A

B

Figure 6. p19Arf Inhibits the Aberrant Bypass of β-Checkpoint in Rag1⁻/⁻ Mice

(A) Representative flow cytometric analyses of CD4 versus CD8 expression on total thymocytes (top) and of CD44 versus CD25 expression on Lin^neg DN thymocytes (bottom) from 16-week-old male $Rag1^{-/-}Arf^{+/+}$, $Rag1^{-/-}Arf^{+/-}$, and $Rag1^{-/-}Arf^{-/-}$ mice. DP cells were detected in only 2 of 12 $Rag1^{-/-}Arf^{-/-}$ mice. The total thymocyte numbers are shown beneath the FACS profiles.
(B) BM cells (1 × 10⁷) from 4-week-old $Rag1^{-/-}Arf^{+/+}$ or $Rag1^{-/-}Arf^{-/-}$ mice (C57BL/6-Ly5.2) were injected into sublethally irradiated recipient mice (C57BL/6-Ly5.1). Representative flow cytometric analyses of CD4 versus CD8 expression on gated Ly5.1⁻/Ly5.2⁺ thymocytes 4 weeks after transplantation are shown. The results are representative of three independent experiments, indicating that DP cells were detected in Ly5.1⁻/Ly5.2⁺ thymocytes in all nine $Rag1^{-/-}Arf^{-/-}$ recipient mice.

amount of 3mH3K27 was markedly reduced. Interestingly, when Ezh2 was removed at the DP stage, thymocyte differentiation and the amount of 3mH3K27 were not affected (Su et al., 2005). We consider that Ezh2 is required for the initiation of 3mH3K27 in early developing thymocytes and that this trimethylation is essential for the DN-DP transition, whereas Ezh2 is dispensable in the maintenance of 3mH3K27 in a later developmental stage, which was consistent with our results. We assume that H3K27 is trimethylated by the PRC2 containing Ezh2 in early progenitor cells and maintained by the PRC1 containing Bmi-1 and M33 during the DN stage.

We propose that Bmi-1 critically contributes to thymocyte proliferation and differentiation by suppressing p19Arf expression and may function as a sensor of the premature cell activation by the induction of cell death. Because Bmi-1 and other PcG genes are involved in tumorigenesis (Raaphorst, 2005; Richie et al., 2002; Valk-Lingbeek et al., 2004), perturbation of this surveillance system may be related to abnormal cell proliferation. Further understanding of the molecular basis of our present findings may provide new insight into lymphomagenesis.

EXPERIMENTAL PROCEDURES

Mice

$Bmi1^{-/-}$ mice were described previously (van der Lugt et al., 1994), and animals used in this study were backcrossd to C57BL/6 more than 8 times. $p19Arf^{-/-}$ mice were described previously (Kamijo et al., 1997) and kindly

provided by C.J. Sherr (St. Jude Children's Hospital). $Trp53^{-/-}$ mice were kindly provided by M. Katsuki (Okazaki National Research Institute). C57BL/6J(B6, Ly5.2) mice were obtained from CREA Japan, and B6 SJL Ptprca Pep3bBoyJ(B6 Ptprc, Ly5.1) mice were obtained from the Jackson Laboratory. The generation of p19Arf Tg mice occurred via the following method. The mouse p19Arf cDNA containing the coding region was cloned into the BamHI site of Lck proximal promoter transgene cassette vector based on the construction described as previously (Allen et al., 1992). A fragment containing the Lck proximal promoter, the mouse p19Arf cDNA, and the human growth hormone gene was excised and purified. The fragment was microinjected into pronuclei of fertilized eggs of C57BL/6 mice. Transgenic mice were identified by Southern blot analysis of the offspring's tail DNAs. Two independent founders carrying the transgene were identified. All mice were kept in accordance with the laboratory animal science guidelines of Hiroshima University. For timed pregnancies, the day of vaginal plug was counted as day 0.5.

Flow Cytometry and Antibodies

Single-cell suspensions from bone marrow, thymus, spleen, and mesenteric lymph node were stained with monoclonal antibodies and second reagents. FITC-, PE-, APC-, APC-Cy7, and biotin-labeled monoclonal antibodies were purchased from BD PharMingen (San Diego, CA) (CD4, CD8α, CD3ε, CD44, CD25, c-kit, Sca-1, CD45R/B220, CD19, Mac-1, Gr-1, Ter119, NK1.1, CD45.2, CD45.1) or from eBiosciences (San Diego, CA) (CD4, CD3ε, CD127, Ter119, CD27). Biotinylated antibodies were revealed with Streptavidin-FITC, -PE, -CyChrome, or APC-Cy7 (BD PharMingen). Clone 2.4G2 anti-CD32:CD16 was used to block Fc receptors. For intracellular staining, sorted DN3 or DN4 cells were fixed with 2% paraformaldehyde and then permiabilized with 0.5% saponin. FACS analysis was performed on a FACS Calibur flow cytometer (Becton Dickinson), and data were analyzed with FlowJo (TreeStar Inc., Ashland, OR) software. For cell sorting, all cells were stained with biotinylated lineage markers, bound to streptavidin-magnetic beads, and depleted of lineage-positive cells by MACS separation column (Milteny Biotech GmbH, Bergisch Gladbach). The lineage-negative cells were then stained with subsequent antibodies as described above. Cells were subsequently sorted with a FACS VantageSE (Becton Dickinson). Dead cells were removed from analysis and sorting by staining with propodium iodide (PI) (Sigma-Aldrich, St. Louis, MO). Reanalysis of the sorted cells indicated a purity greater than 96% for each cell population.

Figure 7. Bmi-1 Binds Directly to the *Ink4a-Arf* Gene Locus, and in Particular to Exon 1β, and Maintains Local 3mH3K27

(A and B) Total thymocyte populations from 3-week-old *Bmi1*[-/-] and littermate control mice were used. Antibodies against acetylated histone H3 and H4, dimethylated histone H3K4 and H3K9, and trimethylated histone H3K27 were used in the ChIP assays. Real-time PCRs were carried out with primers for each amplicon. Two independent experiments were performed with similar results.

(C) Lin[neg] DN and the total thymocyte population from 4-week-old C57BL/6 mice were used for ChIP assays with antibodies against Bmi-1. Probes in which the intensity in Bmi-1 was 3-fold more than that in IgG were defined as "+."

Retroviral Production

pMXs containing an internal ribosomal binding sites (IRES) and green fluorescent protein (GFP) (pMXs-IG) (Kitamura et al., 2003) and Plat-E packaging cells were kindly provided by T. Kitamura (University of Tokyo, Japan). cDNA fragments of *p19Arf* gene was inserted into the EcoRI and XhoI sites of pMx-IG to generate pMXs-p19Arf-IRES-GFP. These vectors were transfected into Plat-E

to obtain the viruses with FuGENE 6 transfection reagent (Roche Diagnostics) according to the manufacturer's recommendations.

FTOC and Retroviral Transduction into Hematopoietic Progenitors

All liquid cultures were performed in RPMI1640 (Invitrogen, Carlsbad, CA) plus 10% FCS for fetal thymus organ cultures (FTOC), 50 μM 2-ME (Nacalai

tesque, Japan), 1 mM sodium pyruvate (Invitorogen), 1× nonessential amino acid solution (Invitorogen), and antibiotics. DN1 cells (Lin^{neg}/CD25$^-$/CD44$^+$/c-kit^{high}) from adult *Bmi1*$^{-/-}$ and control mice (Ly5.2) were sorted and incubated in hanging drop culture with deoxy-guanosine (dGuo)-treated 15.5 dpc fetal tThymic lobes (Ly5.1) overnight, and then maintained in standard FTOC. Cells were analyzed on days 10, 15, and 20. FL cells obtained from 14.5 dpc embryos (Ly5.2) were depleted of Ter119$^+$, Gr1$^+$, and CD19$^+$ cells by magnetic column separation (Miltenyi Biotec) and then cultured overnight in FTOC-Medium with 10 ng/ml stem cell factor (R&D) and 50 U/ml IL-7 (Genzyme). Then, the cells were washed, counted, and replated in 24-well plates in retroviral supernatant (pMXs-IG or pMXs-p19Arf-IG) plus 10 mg/ml polybrene (Sigma), IL-7, and SCF. Viruses were pelleted onto cells by spinning plates at 500 × g for 60 min at 37°C. After 4 hr, cells were aliquoted in FTOC-medium at 10,000 cells/well in Terasaki plates, and 1 deoxy-guanosine-treated (d-Guo) 15.5 dpc B6 *Ptprc* (Ly5.1) thymic lobe per well was added. The cells and lobes were incubated as hanging drop cultures. After 24 hr, each lobe was transferred to standard FTOC conditions, fed weekly, and analyzed after 12 days.

PCR Analysis of TCRβ Rearrangement
Genomic DNA was obtained from sorted DN3 cells with DNAzol Reagent (Invitrogen). Primers were Dβ1, 5'-TTATCTGGTGGTTTCTTCCAGC-3'; Dβ2, 5'-GCACCTGTGGGGAAGAAACT-3'; Jβ2.6, 5'-TGAGAGCTGTCTCCTACTAT CGATT-3'; TCRβ5.1, 5'-GTCCAACAGTTTGATGACTATCAC-2'; TCRββ8.2, CC TCATTCTGGAGTTGGCTACCC-3'. PCR products were electrophoresed through a 1.2% agarose gel and stained with ethidium bromide.

Cell-Cycle Analysis and BrdU Uptake
The amount of nuclear DNA was determined PI staining as follows. Sorted DN3 cells were fixed in 50% ethanol at 4°C for 30 min and incubated in PBS containing 1 mg/ml RNase (Sigma-Aldrich) at 37°C for 20 min. The cells were washed in PBS, resuspended in PBS containing 100 μg/ml PI, and analyzed by a FACS Calibur. For BrdU uptake, mice were injected with 1 mg BrdU (Sigma) twice. Then, thymocytes were isolated 3 hr after first BrdU injection, and DN3 cells were sorted and staining with anti-BrdU Ab (BD) and Hoechist. The BrdU-positive cells among more than 550 cells were counted under microscopy.

TUNEL Assay
Freshly cut 5 μm sections were fixed with acetone at room temperature for 2 min. TUNEL reaction was performed on sections with In Situ Cell Death Detection Kit, Fluorescein (Roche, Mannheim, Germany), according to the manufacturer's protocol. In brief, sections were fixed in 4% paraformaldehyde in PBS for 10 min at room temperature, incubated in 0.1% Triton X-100, 0.1% sodium citrate for 2 min at 4°C, and then incubated in TUNEL reaction mixture for 1 hr at 37°C.

RT-PCR
Semiquantitative RT-PCR was performed on cDNAs obtained from sorted DN3 cells (Lin^{neg}CD44$^-$CD25$^-$c-Kit$^+$) in adult *Bmi1*$^{-/-}$ or littermate control mice. Total RNA was isolated from indicated cells with Trizol Reagent (Invitrogen) and was reverse-transcribed with SuperScript III RT-PCR system (Invitrogen) with oligo(dT) primer. The sequences of the PCR primers were p16Ink4a, 5'-CGCCCAACGCCCCGAACTCT-3'; p19Arf, 5'-GGGTCGCAGGTTCTTGGT CACT-3'; common antisense, 5'-GCTAAGAAGAAAAAGGCGGGCT-3'; INK 4b, 5'-CCGACCCTGCCACCCTTACCA-3'; 5'-CAGATACCTCGCAATGTCAC G-3'; INK4C, 5'-AGGAAAGGGGAAAAAGAGAAGCA-3'; 5'-AACGGACAGCC AACCAACTAAC-3'; INK4D, 5'-GGTCCGCCGCCTTCTTCATCG-3'; 5'-CTCCC ACTCCCTTCTTCAATG-3'; P21CIP, 5'-GCTGGAGGGCAACTTCGTCTGG-3'; 5'-CGTGGGCACTTCAGGGTTTTCT-3'; P27KIP, 5'-ATACGAGTGGCAGGAG GTGGAG-3'; 5'-ATGGGGTGTCAGTTTTGTGTTC-3'; P57KIP, 5'-TCTGAGCA GGGCGAGGAGTC-3'; 5'-CGAAAGGTCCCAGCCGAAGC-3'; GAPDH, 5'-G TGAAGGTCGGTGTGAACGGAT-3'; 5'-CAGAAGGGGCGGAGATGATGAC-3'.

Immunofluorescence
Total thymocyte or sorted DN3 cells were fixed with 4% paraformaldehyde, permiabilized with 1% SDS/0.5% TritonX, and then stained with p19Arf antibody (abcam) and Hoechist.

Bone-Marrow Transplantation
Isolated BM cells from *Rag1*$^{-/-}$*Arf*$^{+/+}$ or *Rag1*$^{-/-}$*Arf*$^{-/-}$ mice (C57BL/6-Ly5.2) were injected into the recipient mice (C57BL/6-Ly5.1) (n = 3) irradiated at a dose of 3.0 Gy (C57BL/6-Ly5.1). 4 weeks after BMT, isolated thymocyte were stained with Ly5.2, Ly5.1, CD4, and CD8 antibodies and analyzed with FACS Calibur.

Chromatin IP
Chromatin immunoprecipitation (ChIP) assay with acetylated H3 and H4 (Upstate Biotechnology), dimethylated H3K9 (abcam), dimethylated H3K4 (Upstate Biotechnology), trimethylated H3K27 (Upstate Biotechnology), Bmi-1 (Upstate Biotechnology), M33 (Katoh-Fukui et al., 2005), and control (Santa Cruz, CA) antibodies was performed as previously described (Ye et al., 2001). In brief, isolated total thymocytes from *Bmi1*$^{-/-}$ and littermate control mice were fixed with formaldehyde for 5 min at room temperature and then soluble chromatin was immunoprecipitated with antibodies overnight. PCR was performed with SYBR Premix Ex Taq for real-time PCR (Takara). The sequences of the PCR primers are available on request. ChIP with Bmi-1 antibody (Upstate Biotechnology) was performed as previously described (Kotake et al., 2007). Purified Lin^{neg} DN cells or total thymocyte from 4-week-old C57BL/6 mice were treated with 1% formaldehyde for 15 min at room temperature and were cell lysed with cell lysis buffer on ice. After centrifugation, the cell pellets were lysed by sonication with nuclear lysis buffer. After procedures mentioned above, PCR was performed with Go Taq Green Master Mix (Promega).

Supplemental Data
Eight figures are available at http://www.immunity.com/cgi/content/full/28/2/231/DC1/.

REFERENCES

Akasaka, T., Tsuji, K., Kawahira, H., Kanno, M., Harigaya, K., Hu, L., Ebihara, Y., Nakahata, T., Tetsu, O., Taniguchi, M., and Koseki, H. (1997). The role of *mel-18*, a mammalian Polycomb group gene, during IL-7-dependent proliferation of lymphocyte precursors. Immunity 7, 135–146.

Allen, J.M., Forbush, K.A., and Perlmutter, R.M. (1992). Functional dissection of the lck proximal promoter. Mol. Cell. Biol. 12, 2758–2768.

Allman, D., Sambandam, A., Kim, S., Miller, J.P., Pagan, A., Well, D., Meraz, A., and Bhandoola, A. (2003). Thymopoiesis independent of common lymphoid progenitors. Nat. Immunol. 4, 168–174.

Bracken, A.P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, C., Theilgaard-Monch, K., Minucci, S., Porse, B.T., Marine, J.C., et al. (2007). The Polycomb group proteins bind throughout the *INK4A-ARF* locus and are disassociated in senescent cells. Genes Dev. 21, 525–530.

Bruggeman, S.W., Valk-Lingbeek, M.E., van der Stoop, P.P., Jacobs, J.J., Kieboom, K., Tanger, E., Hulsman, D., Leung, C., Arsenijevic, Y., Marino, S., and van Lohuizen, M. (2005). *Ink4a* and *Arf* differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev. 19, 1438–1443.

Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R.S., and Zhang, Y. (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039–1043.

Cao, R., Tsukada, Y., and Zhang, Y. (2005). Role of *Bmi1* and *Ring1A* in H2A ubiquitylation and *Hox* gene silencing. Mol. Cell 20, 845–854.

Ciofani, M., and Zuniga-Pflucker, J.C. (2005). Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat. Immunol. 6, 881–888.

Czermin, B., Melfi, R., McCabe, D., Seitz, V., Imhof, A., and Pirrotta, V. (2002). *Drosophila* enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111, 185–196.

Fehling, H.J., and von Boehmer, H. (1997). Early alpha beta T cell development in the thymus of normal and genetically altered mice. Curr. Opin. Immunol. 9, 263–275.

Fischle, W., Wang, Y., Jacobs, S.A., Kim, Y., Allis, C.D., and Khorasanizadeh, S. (2003). Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes Dev. 17, 1870–1881.

Gallagher, S.J., Kefford, R.F., and Rizos, H. (2006). The *ARF* tumour suppressor. Int. J. Biochem. Cell Biol. 38, 1637–1641.

Garbe, A.I., and von Boehmer, H. (2007). TCR and Notch synergize in alphabeta versus gammadelta lineage choice. Trends Immunol. 28, 124–131.

Gil, J., and Peters, G. (2006). Regulation of the *INK4b-ARF-INK4a* tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 7, 667–677.

Gilley, J., and Fried, M. (2001). One *INK4* gene and no *ARF* at the Fugu equivalent of the human *INK4A/ARF/INK4B* tumour suppressor locus. Oncogene 20, 7447–7452.

Hernandez-Munoz, I., Taghavi, P., Kuijl, C., Neefjes, J., and van Lohuizen, M. (2005). Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol. Cell. Biol. 25, 11047–11058.

Hosokawa, H., Kimura, M.Y., Shinnakasu, R., Suzuki, A., Miki, T., Koseki, H., van Lohuizen, M., Yamashita, M., and Nakayama, T. (2006). Regulation of Th2 cell development by Polycomb group gene *Bmi1* through the stabilization of GATA3. J. Immunol. 177, 7656–7664.

Ikawa, T., Masuda, K., Lu, M., Minato, N., Katsura, Y., and Kawamoto, H. (2004). Identification of the earliest prethymic T-cell progenitors in murine fetal blood. Blood 103, 530–537.

Isono, K., Fujimura, Y., Shinga, J., Yamaki, M., O-Wang, J., Takihara, Y., Murahashi, Y., Takada, Y., Mizutani-Koseki, Y., and Koseki, H. (2005). Mammalian polyhomeotic homologues Phc2 and Phc1 act in synergy to mediate polycomb repression of *Hox* genes. Mol. Cell. Biol. 25, 6694–6706.

Itahana, K., Zou, Y., Itahana, Y., Martinez, J.L., Beausejour, C., Jacobs, J.J., Van Lohuizen, M., Band, V., Campisi, J., and Dimri, G.P. (2003). Control of the replicative life span of human fibroblasts by p16 and the polycomb protein *Bmi1*. Mol. Cell. Biol. 23, 389–401.

Iwama, A., Oguro, H., Negishi, M., Kato, Y., Morita, Y., Tsukui, H., Ema, H., Kamijo, T., Katoh-Fukui, Y., Koseki, H., et al. (2004). Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product *Bmi1*. Immunity 21, 843–851.

Jacobs, J.J., Kieboom, K., Marino, S., DePinho, R.A., and van Lohuizen, M. (1999). The oncogene and Polycomb-group gene *Bmi1* regulates cell proliferation and senescence through the *ink4a* locus. Nature 397, 164–168.

Jiang, D., Lenardo, M.J., and Zuniga-Pflucker, J.C. (1996). p53 prevents maturation to the CD4+CD8+ stage of thymocyte differentiation in the absence of T cell receptor rearrangement. J. Exp. Med. 183, 1923–1928.

Kamijo, T., Zindy, F., Roussel, M.F., Quelle, D.E., Downing, J.R., Ashmun, R.A., Grosveld, G., and Sherr, C.J. (1997). Tumor suppression at the mouse *INK4a* locus mediated by the alternative reading frame product p19Arf. Cell 91, 649–659.

Katoh-Fukui, Y., Owaki, A., Toyama, Y., Kusaka, M., Shinohara, Y., Maekawa, M., Toshimori, K., and Morohashi, K. (2005). Mouse Polycomb M33 is required for splenic vascular and adrenal gland formation through regulating Ad4BP/SF1 expression. Blood 106, 1612–1620.

Kawamoto, H., Ohmura, K., Fujimoto, S., Lu, M., Ikawa, T., and Katsura, Y. (2003). Extensive proliferation of T cell lineage-restricted progenitors in the thymus: an essential process for clonal expression of diverse T cell receptor beta chains. Eur. J. Immunol. 33, 606–615.

Kim, S.H., Mitchell, M., Fujii, H., Llanos, S., and Peters, G. (2003). Absence of p16INK4a and truncation of ARF tumor suppressors in chickens. Proc. Natl. Acad. Sci. USA 100, 211–216.

Kimura, M., Koseki, Y., Yamashita, M., Watanabe, N., Shimizu, C., Katsumoto, T., Kitamura, T., Taniguchi, M., Koseki, H., and Nakayama, T. (2001). Regulation of Th2 cell differentiation by mel-18, a mammalian polycomb group gene. Immunity 15, 275–287.

Kirmizis, A., Bartley, S.M., Kuzmichev, A., Margueron, R., Reinberg, D., Green, R., and Farnham, P.J. (2004). Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 18, 1592–1605.

Kitamura, T., Koshino, Y., Shibata, F., Oki, T., Nakajima, H., Nosaka, T., and Kumagai, H. (2003). Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp. Hematol. 31, 1007–1014.

Kotake, Y., Cao, R., Viatour, P., Sage, J., Zhang, Y., and Xiong, Y. (2007). pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev. 21, 49–54.

Maillard, I., Tu, L., Sambandam, A., Yashiro-Ohtani, Y., Millholland, J., Keeshan, K., Shestova, O., Xu, L., Bhandoola, A., and Pear, W.S. (2006). The requirement for Notch signaling at the beta-selection checkpoint in vivo is absolute and independent of the pre-T cell receptor. J. Exp. Med. 203, 2239–2245.

Michie, A.M., and Zuniga-Pflucker, J.C. (2002). Regulation of thymocyte differentiation: pre-TCR signals and beta-selection. Semin. Immunol. 14, 311–323.

Min, J., Zhang, Y., and Xu, R.M. (2003). Structural basis for specific binding of Polycomb chromodomain to histone H3 methylated at Lys 27. Genes Dev. 17, 1823–1828.

Miyazaki, M., Kawamoto, H., Kato, Y., Itoi, M., Miyazaki, K., Masuda, K., Tashiro, S., Ishihara, H., Igarashi, K., Amagai, T., et al. (2005). Polycomb group gene mel-18 regulates early T progenitor expansion by maintaining the expression of Hes-1, a target of the Notch pathway. J. Immunol. 174, 2507–2516.

Muller, J., Hart, C.M., Francis, N.J., Vargas, M.L., Sengupta, A., Wild, B., Miller, E.L., O'Connor, M.B., Kingston, R.E., and Simon, J.A. (2002). Histone methyltransferase activity of a *Drosophila* Polycomb group repressor complex. Cell 111, 197–208.

Negishi, M., Saraya, A., Miyagi, S., Nagao, K., Inagaki, Y., Nishikawa, M., Tajima, S., Koseki, H., Tsuda, H., Takasaki, Y., et al. (2007). Bmi1 cooperates with Dnmt1-associated protein 1 in gene silencing. Biochem. Biophys. Res. Commun. 353, 992–998.

Oguro, H., Iwama, A., Morita, Y., Kamijo, T., van Lohuizen, M., and Nakauchi, H. (2006). Differential impact of *Ink4a* and *Arf* on hematopoietic stem cells and their bone marrow microenvironment in *Bmi1*-deficient mice. J. Exp. Med. 203, 2247–2253.

Park, I.K., Qian, D., Kiel, M., Becker, M.W., Pihalja, M., Weissman, I.L., Morrison, S.J., and Clarke, M.F. (2003). *Bmi1* is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302–305.

Quelle, D.E., Zindy, F., Ashmun, R.A., and Sherr, C.J. (1995). Alternative reading frames of the *INK4a* tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993–1000.

Raaphorst, F.M. (2005). Of mice, flies, and man: the emerging role of polycomb-group genes in human malignant lymphomas. Int. J. Hematol. 81, 281–287.

Raaphorst, F.M., Otte, A.P., van Kemenade, F.J., Blokzijl, T., Fieret, E., Hamer, K.M., Satijn, D.P., and Meijer, C.J. (2001). Distinct BMI1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation. J. Immunol. 166, 5925–5934.

Richie, E.R., Schumacher, A., Angel, J.M., Holloway, M., Rinchik, E.M., and Magnuson, T. (2002). The Polycomb-group gene *eed* regulates thymocyte differentiation and suppresses the development of carcinogen-induced T-cell lymphomas. Oncogene 21, 299–306.

Rocha, S., Campbell, K.J., and Perkins, N.D. (2003). p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol. Cell *12*, 15–25.

Rocha, S., Garrett, M.D., Campbell, K.J., Schumm, K., and Perkins, N.D. (2005). Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. *24*, 1157–1169.

Rothenberg, E.V., and Taghon, T. (2005). Molecular genetics of T cell development. Annu. Rev. Immunol. *23*, 601–649.

Sato, T., Endoh, M., Yoshida, H., Yasuo, S., Katsuno, T., Saito, Y., Isono, K., and Koseki, H. (2006). Mammalian Polycomb complexes are required for Peyer's patch development by regulating lymphoid cell proliferation. Gene *379*, 166–174.

Sherr, C.J. (2006). Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer *6*, 663–673.

Smith, K.S., Chanda, S.K., Lingbeek, M., Ross, D.T., Botstein, D., van Lohuizen, M., and Cleary, M.L. (2003). *Bmi1* regulation of *INK4A-ARF* is a downstream requirement for transformation of hematopoietic progenitors by *E2a-Pbx1*. Mol. Cell *12*, 393–400.

Sparmann, A., and van Lohuizen, M. (2006). Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer *6*, 846–856.

Su, I.H., Dobenecker, M.W., Dickinson, E., Oser, M., Basavaraj, A., Marqueron, R., Viale, A., Reinberg, D., Wulfing, C., and Tarakhovsky, A. (2005). Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell *121*, 425–436.

Sun, Z., Unutmaz, D., Zou, Y.R., Sunshine, M.J., Pierani, A., Brenner-Morton, S., Mebius, R.E., and Littman, D.R. (2000). Requirement for *RORgamma* in thymocyte survival and lymphoid organ development. Science *288*, 2369–2373.

Taghon, T., Yui, M.A., Pant, R., Diamond, R.A., and Rothenberg, E.V. (2006). Developmental and molecular characterization of emerging beta- and gammadelta-selected pre-T cells in the adult mouse thymus. Immunity *24*, 53–64.

Tanigaki, K., Tsuji, M., Yamamoto, N., Han, H., Tsukada, J., Inoue, H., Kubo, M., and Honjo, T. (2004). Regulation of alphabeta/gammadelta T cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling. Immunity *20*, 611–622.

Valk-Lingbeek, M.E., Bruggeman, S.W., and van Lohuizen, M. (2004). Stem cells and cancer; the polycomb connection. Cell *118*, 409–418.

van der Lugt, N.M., Domen, J., Linders, K., van Roon, M., Robanus-Maandag, E., te Riele, H., van der Valk, M., Deschamps, J., Sofroniew, M., van Lohuizen, M., et al. (1994). Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the *Bmi1* proto-oncogene. Genes Dev. *8*, 757–769.

Vire, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.M., et al. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. Nature *439*, 871–874.

Voll, R.E., Jimi, E., Phillips, R.J., Barber, D.F., Rincon, M., Hayday, A.C., Flavell, R.A., and Ghosh, S. (2000). NF-kappa B activation by the pre-T cell receptor serves as a selective survival signal in T lymphocyte development. Immunity *13*, 677–689.

von Boehmer, H., Alfantis, I., Gounari, F., Azogui, O., Haughn, L., Apostolou, I., Jaeckel, E., Grassi, F., and Klein, L. (2003). Thymic selection revisited: how essential is it? Immunol. Rev. *191*, 62–78.

Wolfer, A., Wilson, A., Nemir, M., MacDonald, H.R., and Radtke, F. (2002). Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early alpha beta lineage thymocytes. Immunity *16*, 869–879.

Xi, H., and Kersh, G.J. (2004). Sustained early growth response gene 3 expression inhibits the survival of CD4/CD8 double-positive thymocytes. J. Immunol. *173*, 340–348.

Yamasaki, S., and Saito, T. (2007). Molecular basis for pre-TCR-mediated autonomous signaling. Trends Immunol. *28*, 39–43.

Ye, S.K., Agata, Y., Lee, H.C., Kurooka, H., Kitamura, T., Shimizu, A., Honjo, T., and Ikuta, K. (2001). The IL-7 receptor controls the accessibility of the TCRgamma locus by Stat5 and histone acetylation. Immunity *15*, 813–823.

Yu, Q., Erman, B., Park, J.H., Feigenbaum, L., and Singer, A. (2004). IL-7 receptor signals inhibit expression of transcription factors *TCF-1*, *LEF-1*, and *RORgamma*: impact on thymocyte development. J. Exp. Med. *200*, 797–803.

Zamisch, M., Moore-Scott, B., Su, D.M., Lucas, P.J., Manley, N., and Richie, E.R. (2005). Ontogeny and regulation of IL-7-expressing thymic epithelial cells. J. Immunol. *174*, 60–67.

Zindy, F., Quelle, D.E., Roussel, M.F., and Sherr, C.J. (1997). Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene *15*, 203–211.

Zindy, F., Williams, R.T., Baudino, T.A., Rehg, J.E., Skapek, S.X., Cleveland, J.L., Roussel, M.F., and Sherr, C.J. (2003). Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl. Acad. Sci. USA *100*, 15930–15935.

Original Article

Two flavonoids extracts from *Glycyrrhizae radix* inhibit *in vitro* hepatitis C virus replication

Yuko Sekine-Osajima,[1]* Naoya Sakamoto,[1,2]* Mina Nakagawa,[1,2] Yasuhiro Itsui,[1] Megumi Tasaka,[1] Yuki Nishimura-Sakurai,[1] Cheng-Hsin Chen,[1] Goki Suda,[1] Kako Mishima,[1] Yuko Onuki,[1] Machi Yamamoto,[1] Shinya Maekawa,[3] Nobuyuki Enomoto,[3] Takanori Kanai,[1] Kiichiro Tsuchiya,[1] and Mamoru Watanabe[1]

Department of [1]Gastroenterology and Hepatology and [2]Department for Hepatitis Control, Tokyo Medical and Dental University, Tokyo, and [3]First Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan

Aim: Traditional herbal medicines have been used for several thousand years in China and other Asian countries. In this study we screened herbal drugs and their purified compounds, using the Feo replicon system, to determine their effects on *in vitro* HCV replication.

Methods: We screened herbal drugs and their purified extracts for the activities to suppress hepatitis C virus (HCV) replication using an HCV replicon system that expressed chimeric firefly luciferase reporter and neomycin phosphotransferase (Feo) genes. We tested extracts and 13 purified compounds from the following herbs: *Glycyrrhizae radix*; *Rehmanniae radix*; *Paeoniae radix*; *Artemisiae capillari spica*; and *Rhei rhizoma*.

Results: The HCV replication was significantly and dose-dependently suppressed by two purified compounds, isoliquiritigenin and glycycoumarin, which were from *Glycyrrhizae radix*. Dose-effect analyses showed that 50% effective concentrations were 6.2 ± 1.0 µg/mL and 15.5 ± 0.8 µg/mL for isoliquiritigenin and glycycoumarin, respectively. The MTS assay did not show any effect on cell growth and viability at these effective concentrations, indicating that the effects of the two compounds were specific to HCV replication. These two compounds did not affect the HCV IRES-dependent translation nor did they show synergistic action with interferon-alpha.

Conclusion: Two purified herbal extracts, isoliquiritigenin and glycycoumarin, specifically suppressed *in vitro* HCV replication. Further elucidation of their mechanisms of action and evaluation of *in vivo* effects and safety might constitute a new anti-HCV therapeutics.

Key words: hepatitis C virus, herbal drugs, replicon

INTRODUCTION

HEPATITIS C VIRUS (HCV) infects 170 million people worldwide and is characterized by chronic liver inflammation and fibrogenesis leading to end-stage liver failure and hepatocellular malignancy.[1,2] The difficulty in eradicating HCV is attributable, in part, to limited treatment options against the virus. Currently, combination therapy using pegylated interferon-alpha (IFN) and ribavirin has been used worldwide.[3-5] The success rates, however, are almost half of patients

treated. Furthermore, these therapies carry a significant risk of serious side effects. Thus, the development of alternative therapeutic agents against HCV is our high priority goal.

We have reported an HCV subgenomic replicon that expresses chimeric luciferase reporter "Feo" protein.[6] This Feo replicon supports stable and high levels of autonomous HCV RNA replication in transfected cells. Furthermore, the level of luciferase correlates well with levels of HCV RNA production, so that luciferase can be used as a reliable surrogate marker for HCV replication. This chimeric reporter replicon system has contributed the discovery of novel anti-HCV substances such as cyclosporins,[7-9] short interfering RNA,[10,11] interferon-gamma[12] and HMG-CoA reductase inhibitors.[13,14]

Traditional herbal drugs have been used for several thousand years in China and other Asian countries. Although these pharmacological activities are not fully

60

Table 1 List of herbal drugs and their purified extracts

Herbal drug	Purified compound
Glycyrrhizae radix	Isoliquiritigenin
	Glycycoumarin
	Isoliquiritin
	Licuroside
Paeoniae radix	Paeoniflorin
	1,2,3,6-tetra-O-galloyl-β-D-glucose
Rhei Rhizoma	Rhein 8-O-β-glucoside
Rehmanniae radix	Acteoside
	Martynoside
	Isoacteoside
Artemisiae	Demethoxycapillarisin
capillari spica	3,4-di-o-galloylquinic acid
	Acteosyringone

characterized, they also have been safely used for many clinical conditions in Japan. For example, Sho-saiko-to (TJ-9; Xiao-Chae-Hu-Tang in Chinese), an oral medicine, which consists of seven herbal components (*Bupleuri radix, Pinelliae tuber, Scutellariae radix, Ginseng radix, Grycyrrhizae radix, and Zingiberis rhizoma*),[15] has been clinically used for the treatment of chronic viral liver disease. It has been reported to regulate the cytokine production system in patients with hepatitis C[16] and to prevent the development of HCC in patients with non-B cirrhosis.[17] *Glycyrrhizin*, the major component of *Glycyrrhizae radix* (licorice), has also been used for the treatment of chronic hepatitis in Japan, known to have an alanine transaminase-lowering effect.[18,19] Despite the clinical effects of these herbal drugs, they did not suppress the HCV replication *in vitro*.[15]

In the present study, we applied the Feo replicon system to screen the herbal drugs and their purified compounds for their effects on *in vitro* HCV replication. Here, we show that two purified compounds from the herbal extracts specifically and substantially suppressed HCV replication.

## MATERIALS AND METHODS

Purified compounds (Table 1)

THIRTEEN COMPOUNDS WERE purified from five herbal drugs: *Glycyrrhizae radaix; Rhemanniae radix; Paeoniae radix; Artemisiae Capillari Spica*; and *Rhei Rhizoma* (Table 1; Tsumura, Tokyo, Japan). These extracts were prepared at concentrations of 5 mg/mL in dimethyl sulfoxide (DMSO), then stored at −20°C until use. Recombinant human interferon (IFN) alpha-2b was obtained from Schering-Plough (NJ, USA).

Cell culture

A human hepatoma cell line, Huh7, was maintained in Dulbecco's modified Eagle's medium (Sigma, MO, USA) supplemented with 10% fetal calf serum at 37°C under 5% CO_2. Huh7 cells expressing the HCV replicon were cultured in a medium containing 200 μg/mL G418 (Wako, Osaka, Japan).

HCV subgenomic replicon construct

An HCV subgenomic replicon plasmid, pHCV1bneo-delS,[20] was reconstructed by substituting the neomycin phosphotransferase gene with a fusion gene comprising the firefly luciferase and neomycin phosphotrasnferase (pRep-Feo) (Fig. 1a). RNA was synthesized from pRep-

Figure 1 HCV subgenomic replicon and reporter plasmid constructs. (a) An HCV subgenomic replicon plasmid, pRep-Feo, was reconstructed from HCV1bneo-delS by replacing the neomycin phosphotransferase (Neo) gene with a fusion gene comprising the firefly luciferase (Fluc) and Neo, which we designated as "Feo"*. NS, nonstructural region; pT7, T7 promoter; 3′ UTR, 3′ untranslated region. (b) A plasmid, pCIneo-Rluc-IRES-Fluc, was constructed to analyze HCV-IRES-mediated translation efficiency . The plasmid, expressing a bicistronic RNA, in which *Renilla* luciferase (Rluc) was translated in a cap-dependent manner and firefly luciferase (Fluc) was translated by HCV-internal ribosome entry site (IRES)-mediated initiation, was stably transfected into Huh7 cells.

Feo and transfected into Huh7 cells. After culture in the presence of G418, cell lines stably expressing the replicon were established.[10,21]

HCV-IRES reporter construct

A plasmid, pCIneo-Rluc-IRES-Fluc, was used to analyze HCV internal ribosome entry site (IRES)-mediated translation efficiency (Fig. 1b).[22] The plasmid, expressing a bicistronic RNA, in which *Renilla* luciferase (Rluc) was translated in a cap-dependent manner and firefly luciferase (Fluc) was translated by HCV-IRES-mediated initiation, was stably transfected into Huh7 cells. After culture in the presence of G418, Huh7/CRIF cells were established.[9] Activities of the HCV-IRES-mediated translation were measured by culture of Huh7/CRIF cells in the presence of drugs and by dual luciferase assays after 48 h.

Luciferase assays and measurements of antiviral activity

Huh7/Rep-Feo cells were cultured with various concentrations of herbal extracts or compounds. Levels of HCV replication were quantified by internal luciferase assay after 48 h of culture. Luciferase activities were quantified using a luminometer (Promega, WI, USA) and the Bright-Glo Luciferase Assay System (Promega). Assays were performed in triplicate and the results were expressed as means ± SD as percentages of the controls. The 50% effective concentrations (EC50) were calculated using probit method. The determination of EC50 was performed three times, and presented as mean ± SD in each compound.

Realtime RT-PCR analysis

Total cellular RNA was extracted from cultured cells or liver tissue using ISOGEN (Nippon Gene, Tokyo, Japan). Two µg of total cellular RNA was used to generate cDNA from each sample using the SuperScript II reverse-transcriptase (Invitrogen, CA, USA). The replicon RNA expression levels were measured using the Applied Biosystems 7500 Fast Realtime PCR System (Applied Biosystems, CA, USA) and QuantiTect SYBR Green PCR Kit (QIAGEN, CA, USA). Sequences of a pair of primers has been described elsewhere.[23]

Northern blottings

Expression of HCV subgenomic RNA was detected as previously reported.[24] Total cellular RNA was extracted from cells using ISOGEN (Nippon Gene, Tokyo, Japan). Fifteen micrograms of the total cellular RNA was electrophoresed on a 1.0% denaturing agarose-

formaldehyde gel and was transferred to a Hybond-N+ nylon membrane (Amersham-Pharmacia Biotech, Sweden). The upper part of the membrane, which contained the HCV replicon RNA, was hybridized with a digoxigenin-labeled probe that was specific for the full-length replicon sequence, and the lower part of the membrane was hybridized with a probe specific for beta-actin. The signals were detected in a chemiluminescence reaction using a Digoxigenin Luminescent Detection Kit (Roche, Germany) and visualized using a Fluoro-Imager (Roche).

Western blottings

Western blotting was done as reported previously.[24] Thirty micrograms of total cell lysate was separated using NuPAGE 4–12% Bis-Tris gels (Invitrogen, CA, USA) and blotted onto an Immobilon polyvinylidene difluoride membrane (Roche). The membrane was incubated with the primary antibodies followed by a peroxidase-labeled anti IgG antibody, and visualized by chemiluminescence reaction (BM Chemiluminescence Blotting Substrate; Roche). The antibodies used were anti-NS5A (BioDesign, ME, USA), anti-core (provided by Dr. Wakita), and anti-beta-actin antibodies (Sigma).

MTS assays

To evaluate cell viability, MTS (dimethylthiazol carboxymethoxyphenyl sulfophenyl tetrazolium) assays were performed using a Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega) according to manufacturer's directions.

HCV-JFH1 virus cell culture

An *in vitro* transcribed HCV-JFH1 RNA[25] was transfected into Huh7.5.1 cells.[26] Naïve Huh7.5.1 cells were subsequently infected by culture supernatant of the JFH1-RNA transfected Huh-7.5.1 cells, and subjected to culture in the presence of drugs. Culture medium was collected serially and HCV core antigen was measured using a chemiluminescence enzyme immunoassay (CLEIA) according to the manufacturer's protocol (Lumipulse Ortho HCV Antigen; Ortho-Clinical Diagnostics, Tokyo, Japan). Cellular virus expression was measured by the Western blotting using anti-core antibodies.[27]

Statistical analyses

Statistical analyses were performed using Student's *t*-test. *P*-values of less than 0.05 were considered statistically significant.

RESULTS

Suppression of HCV replication by purified herbal extracts, isoliquiritigenin and glycycoumarin

TO SCREEN THE herbal drugs and these purified extracts (Table 1) for their antiviral effects against HCV replication, Huh7/Rep-Feo cells were cultured with various concentrations of 5 herbal extracts; *Glycyrrhizae radaix, Rhemanniae radix, Paeoniae radix, Artemisiae capillari spica, and Rhei rhizoma*, and 13 compounds purified from these herbal extracts. Levels of HCV replication were quantified by internal luciferase assay after 48 h. None of the herbal extracts showed any effects on HCV replication (data not shown). On the other hand, among the 13 purified compounds, isoliquiritigenin and glycycoumarin, which were purified from *Glycyrrhizae radix*, suppressed replication of HCV replicon in a dose-dependent manner. The EC50s were 6.2 ± 1.0 and

$15.5 \pm 0.8 \mu g/mL$ for isoliquiritigenin and glycycoumarin, respectively (Figs 2a,3a). The MTS assay did not show any effect on cell growth and viability (Fig. 2b), indicating that the antiviral action of the two compounds is not due to cytotoxic or antiproliferative effects. Huh7/Rep-Feo cells were cultured with various concentrations of isoliquiritigenin and glycycoumarin, and the dose-effect correlation and time courses of replicon expression were measured by luciferase assay. After addition of each compounds, suppressive effect of the HCV replicon lasted for 48 h in a dose and time-dependent manner (Fig. 3b).

Realtime-RT-PCR and Western blotting analyses

In the realtime RT-PCR analysis and Northern blot analyses, levels of the replicon RNA decreased in a dose-dependent manner following treatment with isoliquir-


Figure 2 Effects of purified extracts from herbal drugs on expression of HCV replicon. (a) Huh7/Rep-Feo cells, which constitutively express the HCV Feo replicon, were cultured in the presence of 13 compounds at concentrations of 0, 0.1, 1, and 10 μg/mL. The internal luciferase activities were measured after 48 h of culture. Assays were performed in triplicate. Error bars indicate mean ± SD. Asterisks indicate p-values of less than 0.05. (b) MTS assay of Huh7/Rep-Feo cells cultured with the concentrations of 13 compounds indicated. Error bars indicate mean ± SD.

Figure 3 Dose- and time-dependent suppression of HCV replication by isoliquiritinenin and glycycoumarin. (a) Relative log (dose)-response plots for isoliquiritigenin or glycycoumarin. Error bars indicate mean ± SD of triplicate analyses. Calculated probit curves are overlaid in each plot. (b) Huh7/Rep-Feo cells were cultured with the concentrations of isoliquiritigenin and glycycoumarin indicated. The internal luciferase activities were measured at times of culture indicated. Assays were performed in triplicate. Error bars indicate mean ± SD.

itigenin and glycycoumarin (Fig. 4a,b). Similarly, in Western blot analysis, the HCV non-structural protein, NS5A, which was translated from the HCV replicon, decreased by corresponding amounts in response to treatment with isoliquiritigenin and glycycoumarin (Fig. 4c). Densitometric analysis of NS5A protein showed that the intracellular levels of the virus protein in Huh7/Rep-Feo cells correlated well with the luciferase activities.

Absence of synergistic anti-HCV effects of interferon-alpha with isoliquiritigenin or glycycoumarin

To determine whether IFN and these two compounds have a synergistic inhibitory effect on the replicon, Huh7/Rep-Feo cells were cultured with combinations of IFNα-2b and isoliquiritigenin or glycycoumarin at various concentrations. The relative dose-inhibition curves of IFN were plotted under each fixed concentrations of isoliquiritigenin or glycycoumarin of 0, 0.1, 1, 10 μg/mL, respectively (Fig. 5). The curves did not show synergy of the two compounds and IFN against the HCV replicon. To see whether the action of isoliquiritigenin and glycycoumarin involve interferon-Jak/STAT-ISRE pathway, we conducted ISRE reporter assays. We transfected the p-55C1BLuc plasmid in Huh7 cells and cultured the cells in the presence of isoliquiritigenin or

glycycoumarin. After 12 h of incubation, those drugs did not activate ISRE-promoter activities (data not shown). These results suggested that the action of the compounds on the intracellular replication of HCV replicon was independent of the IFN-ISRE pathway.

Isoliquiritigenin and glycycoumarin do not suppress the HCV IRES-dependent translation

We next determined whether these two compounds suppress HCV IRES-dependent translation, we used Huh7 cell line that had been stably transfected with pCIneo-Rluc IRES-Fluc (Huh7/CRIF; Fig. 1b). Treatment of these cells with isoliquiritigenin or glycycoumarin resulted in no significant change of the internal luciferase activities at concentrations of these two compounds that suppressed expression of the HCV replicon (Fig. 6a). The MTS assay did not show any effect on cell growth and viability at concentrations used in this assay (Fig. 6b).

Isoliquiritigenin and glycycoumarin suppress HCV-JFH1 virus cell culture

The demonstrated inhibitory effects isoliquiritigenin and glycycoumarin on HCV subgenomic replication were validated further by using HCV-JFH1 cell culture system.[25] As shown in Figure 7a, treatment of the cells with the two compounds suppressed time-dependent

Figure 4 Suppression of replicon RNA and NS5A synthesis by isoliquiritigenin and glycycoumarin. Huh7/Rep-Feo cells were cultured with indicated concentrations of two compounds, isoliquiritigenin and glycycoumarin, and harvested at 48 hr after exposure. (a) Real-time RT-PCR analyses. (b) Northern-blot hybridization. Fifteen micrograms of total cellular RNA was electrophoresed in each lane. The upper part of the membrane containing the hepatitis C virus replicon RNA was hybridized with a digoxigenin-labeled probe specific for the replicon sequence, and the lower part was hybridized with beta-actin probe. Densitometry for replicon RNA was performed and indicated as percents of drug-negative control. (c) Western blotting. Thirty micrograms of total cellular protein was electrophoresed in each lane. Densitometry of NS5A protein was performed and indicated as percents of drug-negative control.

increase of HCV core antigen in the medium. In all time points, core antigen levels were significantly lower in culture that were treated with isoliquiritigenin and glycycoumarin than the untreated culture. The effect of glycycoumarin was partly reversed on day six probably due to chemical instability of the compound. Consistently, the Western blot showed that the cellular HCV core protein expression was substantially suppressed by treatment with isoliquiritigenin and glycycoumarin (Fig. 7b).

Figure 5 Effects of (a) isoliquiritigenin and (b) glycycoumarin used in combination with interferon(IFN)-α on HCV replication. Huh7/Rep-Feo cells were cultured with combinations of IFN-α-2b and isoliquiritigenin or glycycoumarin at concentrations indicated. The internal luciferase activities were measured after 48 h of culture. Assays were performed in triplicate. Error bars indicate mean ± SD. Plots of 100% in each curves represent replicon expression levels that were treated with indicated amounts of isoliquiritigenin or glycycoumarin and without IFN.

DISCUSSION

THE PRESENT STUDY demonstrates that two purified herbal extracts, isoliquiritigenin and glycycoumarin, isolated from *Glycyrrhizae radix*, suppress replication of an HCV replicon (Fig. 2). Northern and Western blot analyses reveal that both RNA synthesis and its translation were reduced by the two compounds in dose- and time-dependent manners (Figs 3,4). The two drugs did not show activation of type-I interferon-dependent, ISRE-mediated transcription or synergistic action with interferon-alpha on HCV replication (Fig. 5,6), which suggests that the anti-HCV effects of the compounds are independent of interferon-antiviral mechanisms. Finally, we have demonstrated that the two compounds show inhibitory effects on HCV virus cell cultures (Fig. 7).

Flavonoid is a class of plant pigment, found in wide range of green vegetables and fruits. They are classified into flavon, flavonol, flavanone, flavanol, isoflavone, chalcone, anthocyanin and catechin, according to their molecular structures. Many flavonoids have various biological functions such as antibacterial,[28] antioxidative and anticarcinogeninc activities.[29] Isoliquiritigenin is a simple chalcon derivative and found in licorice and vegetables including shallots and bean sprouts. Isoliquiritigenin has several biochemical activities similar to other flavonoids. It has various biochemical activities such as antioxidative and superoxide scavenging activities,[30] an antiplatelet aggregation effect,[31] an inhibitory effect on aldose reductase activity,[32] estrogenic properties[33] and selective inhibition of H2 receptor-mediated signaling.[34]

Figure 6 Isoliquiritigenin and glycycoumarin do not influence the HCV IRES-mediated translation. A bicistronic reporter gene plasmid, pCIneo-Rluc-IRES-Fluc, was stably trasfected into Huh7 cells (Huh7/CRIF , *see* the Methods). (a) Dual luciferase assay. The cells were cultured with isoliquiritigenin or glycycoumarin at the concentrations indicated, and dual luciferase activities were measured after 48 h of treatment. Values are displayed as ratios of Fluc to Rluc. Error bars indicated mean ± SD. (b) MTS assay of Huh7/neo-Rluc-IRES-Fluc cells cultured with isoliquiritigenin or glycycoumarin at the concentrations indicated. MTS assays at 48 h after treatment with each drug were performed in triplicate. Error bars indicate mean + SD.

(a)

(b)

Figure 7 Suppresion of HCV-JFH1 virus expression by *isoliquiritigenin and glycycoumarin*. (a) Naïve Huh 7.5.1 cells were infected with culture supernatant of HCV-JFH1-infected cells and were subjected to culture in the presence of indicated drugs. Culture supernatants were collected at indicated days, and HCV core antigen was measured. Assays were done in triplicate and indicated as mean ± SD. (b) Cells were harvested at day 6, and Western blotting was performed using anti-core and anti-beta-actin antibodies.

Extracts of a licorice root, *Glycyrrhizae radix*, show anti-inflammatory properties in chronic and acute liver inflammation,[35] and are widely and extensively prescribed in Japan as Strong Neominophagen C (SNMC). A major ingredients of *Glyzyrrizae radix* are glycyrrhizin and liquiritin. However, glycyrrhizin and liquiritin did not suppress HCV replication, suggesting that the commercially available SNMC will not elicit antiviral effects against HCV. On the other hand, there have been reports on the pharmacological action of glycycoumarin. Glycycoumarin displays antibacterial properties in the upper respiratory tract in infections such as *Streptococcus pyogenes*, *Haemophilus infuenzae* and *Moraxella*

catarrhalis,[36] and methicillin-resistant *Staphylococcus aureus*,[37] but the mechanisms of action is unclear.

To our knowledge, there have been no reports on the serum concentration of glycycoumarin and isoliquiritigenin in patients taking medicines or dietary supplements containing *Glyzyrrizae radix*. However, therapeutic doses of 3–12 g per day of powdered root have been suggested for pathological conditions including chronic hepatitis, muscle cramp, acute gastritis, and urolithiasis. Thus, further studies are required to assess the human exposure to these flavonoids, the pharmacological dose-dependent properties and the tissue distribution and drug kinetics.

Considering the current status of limited therapy options for HCV infection and their unsatisfactory outcomes, large scale screening of anti-HCV molecules for the development of novel antiviral therapies is called for. In the present study, we have screened Chinese herbal extracts for the ability to suppress HCV replication, and identified two extracts, isoliquiritigenin and glycycoumarin, which specifically suppressed HCV replication. These results suggest that these agents will be a promising for use in the stabilization of HCV replication and active liver inflammation. In addition, further investigations of the action of these drugs on the expression, processing or maturation of HCV proteins may elucidate new aspects of the viral infection and replication and may constitute novel molecular targets for anti-HCV chemotherapeutics.

ACKNOWLEDGEMENTS

REFERENCES

1 Alter MJ. Epidemiology of hepatitis C. *Hepatology* 1997; **26**: 62S–65S.
2 Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. *N Engl J Med* 1995; **332**: 1463–6.
3 Fried MW, Shiffman ML, Reddy KR *et al.* Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; **347**: 975–82.

4 Hadziyannis SJ, Sette H Jr, Morgan TR *et al.* Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; **140**: 346–55.

5 Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. *J Gastroenterol* 2006; **41**: 17–27.

6 Tanabe Y, Sakamoto N, Enomoto N *et al.* Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. *J Infect Dis* 2004; **189**: 1129–39.

7 Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. *Hepatology* 2003; **38**: 1282–8.

8 Nakagawa M, Sakamoto N, Enomoto N *et al.* Specific inhibition of hepatitis C virus replication by cyclosporin A. *Biochem Biophys Res Commun* 2004; **313**: 42–7.

9 Nakagawa M, Sakamoto N, Tanabe Y *et al.* Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. *Gastroenterology* 2005; **129**: 1031–41.

10 Yokota T, Sakamoto N, Enomoto N *et al.* Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. *EMBO Rep* 2003; **4**: 602–8.

11 Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. *Proc Natl Acad Sci USA* 2003; **100**: 2014–18.

12 Frese M, Schwarzle V, Barth K *et al.* Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. *Hepatology* 2002; **35**: 694–703.

13 Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. *Hepatology* 2006; **44**: 117–25.

14 Kim SS, Peng LF, Lin W *et al.* A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. *Gastroenterology* 2007; **132**: 311–20.

15 Kanda T, Yokosuka O, Imazeki F *et al.* Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. *J Viral Hepat* 2004; **11**: 479–87.

16 Yamashiki M, Nishimura A, Suzuki H, Sakaguchi S, Kosaka Y. Effects of the Japanese herbal medicine "Sho-saiko-to" (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. *Hepatology* 1997; **25**: 1390–7.

17 Oka H, Yamamoto S, Kuroki T *et al.* Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). *Cancer* 1995; **76**: 743–9.

18 Arase Y, Ikeda K, Murashima N *et al.* The long term efficacy of glycyrrhizin in chronic hepatitis C patients. *Cancer* 1997; **79**: 1494–500.

19 van Rossum TG, Vulto AG, Hop WC, Schalm SW. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. *Am J Gastroenterol* 2001; **96**: 2432–7.

20 Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. *J Virol* 2001; **75**: 8516–23.

21 Tanabe Y, Sakamoto N, Enomoto N *et al.* Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha. *J Infect Dis* 2004; **189**: 1129–39.

22 Itsui Y, Sakamoto N, Kurosaki M *et al.* Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. *J Viral Hepat* 2006; **13**: 690–700.

23 Sakamoto N, Sato C, Haritani H *et al.* Detection of hepatitis C viral RNA in sporadic acute non-A, non-B hepatitis by polymerase chain reaction. Its usefulness for the early diagnosis of seronegative infection. *J Hepatol* 1993; **17**: 28–33.

24 Yamashiro T, Sakamoto N, Kurosaki M *et al.* Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3. *J Gastroenterol* 2006; **41**: 750–7.

25 Wakita T, Pietschmann T, Kato T *et al.* Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat Med* 2005; **11**: 791–6.

26 Zhong J, Gastaminza P, Cheng G *et al.* Robust hepatitis C virus infection in vitro. *Proc Natl Acad Sci USA* 2005; **102**: 9294–9.

27 Sekine-Osajima Y, Sakamoto N, Nakagawa M *et al.* Development of plaque assays for hepatitis C virus and isolation of mutants with enhanced cytopathogenicity and replication capacity. *Virology* 2008; **371**: 71–85.

28 Arima H, Ashida H, Danno G. Rutin-enhanced antibacterial activities of flavonoids against Bacillus cereus and Salmonella enteritidis. *Biosci Biotechnol Biochem* 2002; **66**: 1009–14.

29 Musonda CA, Chipman JK. Quercetin inhibits hydrogen peroxide (H_2O_2)-induced NF-kappaB DNA binding activity and DNA damage in HepG2 cells. *Carcinogenesis* 1998; **19**: 1583–9.

30 Haraguchi H, Ishikawa H, Mizutani K, Tamura Y, Kinoshita T. Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata. *Bioorg Med Chem* 1998; **6**: 339–47.

31 Tawata M, Aida K, Noguchi T *et al.* Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. *Eur J Pharmacol* 1992; **212**: 87–92.

32 Aida K, Tawata M, Shindo H *et al.* Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix. *Planta Med* 1990; **56**: 254–8.

33 Tamir S, Eizenberg M, Somjen D, Izrael S, Vaya J. Estrogen-like activity of glabrene and other constituents isolated from licorice root. *J Steroid Biochem Mol Biol* 2001; **78**: 291–8.

34 Kim DC, Choi SY, Kim SH *et al.* Isoliquiritigenin selectively inhibits H(2) histamine receptor signaling. *Mol Pharmacol* 2006; **70**: 493–500.

35 Finney RS, Somers GF. The antiinflammatory activity of glycyrrhetinic acid and derivatives. *J Pharm Pharmacol* 1958; **10**: 613–20.

36 Tanaka Y, Kikuzaki H, Fukuda S, Nakatani N. Antibacterial compounds of licorice against upper airway respiratory tract pathogens. *J Nutr Sci Vitaminol (Tokyo)* 2001; **47**: 270–3.

37 Hatano T, Shintani Y, Aga Y, Shiota S, Tsuchiya T, Yoshida T. Phenolic constituents of licorice. VIII. Structures of glicophenone and glicoisoflavanone, and effects of licorice phenolics on methicillin-resistant Staphylococcus aureus. *Chem Pharm Bull (Tokyo)* 2000; **48**: 1286–92.

Original Article

Griseofulvin, an oral antifungal agent, suppresses hepatitis C virus replication *in vitro*

Haofan Jin,[1] Atsuya Yamashita,[1] Shinya Maekawa,[2] Pinting Yang,[1,3] Limin He,[1] Satoru Takayanagi,[1] Takaji Wakita,[4] Naoya Sakamoto,[5] Nobuyuki Enomoto[2] and Masahiko Ito[1]

[1]*Department of Microbiology,* [2]*First Department of Internal Medicine, University of Yamanashi, Yamanashi, and* [5]*Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan;* [3]*Department of Rheumatology and Immunology, China Medical University, Shenyang, China; and* [4]*Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan*

Aim: Hepatitis C virus (HCV), which infects an estimated 170 million people worldwide, is a major cause of chronic liver disease. The current standard therapy for chronic hepatitis C is based on pegylated interferon (IFN)α in combination with ribavirin. However, the success rate remains at approximately 50%. Therefore, alternative agents are needed for the treatment of HCV infection.

Methods: Using an HCV-1b subgenomic replicon cell culture system (Huh7/Rep-Feo), we found that griseofulvin, an oral antifungal agent, suppressed HCV-RNA replication and protein expression in a dose-dependent manner. We also found that griseofulvin suppressed the replication of infectious HCV JFH-1. A combination of IFNα and griseofulvin exhibited a synergistic inhibitory effect in Huh7/Rep-Feo cells.

Results: We found that griseofulvin blocked the cell cycle at the G_2/M phase in the HCV subgenomic replicon cells, but did not inhibit HCV internal ribosome entry site-dependent translation.

Conclusion: Our results suggest that griseofulvin may represent a new approach to the development of a novel therapy for HCV infection.

Key words: cell cycle, griseofulvin, hepatitis C virus internal ribosome entry site, hepatitis C virus replicon, JFH-1

INTRODUCTION

HEPATITIS C VIRUS (HCV) is an etiologic agent of chronic liver disease,[1,2] and it is estimated that approximately 170 million people worldwide are infected with the virus. Chronic hepatitis C can lead to severe liver diseases, including fibrosis, cirrhosis, and hepatocellular carcinoma.[3] With advancements in HCV therapy, including the most recent combination of pegylated interferon (IFN)α and ribavirin, up to one-half of patients achieve a sustained virological response.

However, the remainder cannot clear the virus, demonstrating a great need for more powerful therapeutic modalities.[4]

Investigations have been hampered by the lack of an efficient HCV cell culture system. In 1999, the establishment of an HCV subgenomic replicon cell culture system improved the situation. The subgenomic replicon RNA is composed of the HCV 5′ untranslated region (UTR) containing the internal ribosomal entry site (IRES), a neomycin phosphotransferase (neo) gene and the HCV non-structural (NS) proteins through 3–5B under the control of an encephalomyocarditis virus (EMCV) IRES, followed by the HCV 3′ UTR.[5] A HCV replicon carrying, in addition to the selectable marker, a gene encoding luciferase, can be used to screen a large number of compounds for antiviral activity.[6–8] The recent development of an *in vitro* HCV infection system provides an opportunity to evaluate inhibitors of all stages of the HCV life cycle.[9–11]

909

Currently, proof of concept has been obtained in clinical trials of three different HCV NS3 protease inhibitors, BILN 2061,[12,13] telaprevir (VX-950),[14] and SCH 503034.[15] However, because of many factors, including possible side-effects and the emergence of drug-resistant mutants, there is still great need for improved therapies. We focused therefore on screening a set of licensed drugs which have not been recommended previously for antiviral use. Here, we found that the oral antifungal agent, griseofulvin, had a suppressive effect on HCV replication, assessed using the HCV-1b subgenomic replicon system and the particle-producing cell culture HCV-2a model of JFH-1. The mechanism of the anti-HCV activity of griseofulvin also was studied.

METHODS

Cell cultures and HCV replicon

THE HUMAN HEPATOMA cell line, Huh7, was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin. For subgenomic replicon Huh7/Rep-Feo (HCV 1b replicon that expresses a chimeric protein consisting of neomycin phosphotransferase and firefly luciferase) cells,[7,8] the culture medium was supplemented with 250 g/mL G418. Huh 7.5.1/JFH-1 cells (Huh 7.5.1 chronically infected HCV JFH-1) were maintained in DMEM supplemented with 10% (v/v) fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin.[16]

Reagents

Griseofulvin and fluconazole were purchased from Wako Pure Chemical (Tokyo, Japan). Itraconazole was purchased from LKT Laboratories (St Paul, MN, USA). Recombinant human IFNα-2b was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Cell viability assays

For griseofulvin and fluconazole, viable cell growth was determined by a 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazoly)-3-(4-sulfophenyl) tetrazolium inner salt (MTS) reduction assay using the Cell Titer 96 aqueous one solution cell proliferation assay (Promega, Madison, WI, USA), according to the manufacturer's protocol.

For itraconazole, viable cell growth was determined using the CellTiter-Glo luminescent cell viability assay (Promega, USA), according to the manufacturer's protocol.

Luciferase activity assays

Typically, Huh7/Rep-Feo cells were seeded in a 48-well plate at a density of 2×10^4 cells per well. Compounds were added to the culture medium at various concentrations. After 72 h of culture, the expression levels of the HCV replicon were measured by luciferase assay using the luciferase assay system (Promega, USA) and the Luminescencer-JNR AB-2100 (Atto, Tokyo, Japan).

The Huh7 cells stably transfected with the pEF Fluc IN vector were mock treated (control) or treated with 20 µM or 40 µM griseofulvin. After 72 h of culture, luciferase assays were performed using the luciferase assay system and the Luminescencer-JNR AB-2100. Luciferase activity was normalized by the protein concentration, measured using a BCA protein assay kit (Pierce, Rockford, IL, USA).

The Huh7 cells stably transfected with the pEF Rluc-HCV IRES Feo vector were mock treated (control) or treated with 20 µM griseofulvin. Dual luciferase activities were carried out at 8, 16, 24, and 32 h after exposure to griseofulvin using the dual luciferase reporter assay system and the Luminescencer-JNR AB-2100.

All assays were performed in triplicate, and the results were expressed as mean ± SD relative light units.

RNA analysis

Total cellular RNA was extracted from the Huh7/Rep-Feo cells using the RNAqueous-4PCR kit (Ambion, Austin, TX, USA). RNA was reverse transcribed with a Thermoscript reverse transcriptase kit (Invitrogen, Carlsbad, CA, USA).

Quantitative real-time polymerase chain reaction (PCR) was carried out using ABI Prism 7500 (Applied Biosystems, Foster City, CA, USA). The forward and reverse primers for the 5′ UTR of HCV-RNA were 5′-TGCGGAACCGGTGAGTACA-3′ and 5′-CTTAAGG TTTAGGATTCGTGCTCAT-3′, respectively. The fluorogenic probe used for the quantification of HCV-RNA was 5′-(FAM)-CACCCTATCAGGCAGTA-CCACAAGG CC-(TAMRA)-3′. Human 18S ribosomal RNA levels in the samples were analyzed by quantitative real-time PCR to normalize the RNA content. The forward and reverse primers for human 18S ribosomal RNA were 5′-ACTCTAGATAACCTCGGGCCGA-3′ and 5′-GATGT GGTAGCCGTTTCTCAGG-3′, respectively. The fluorogenic probe used for quantification of human 18S ribo-

somal RNA was 5′-(FAM)-CCATTCGAACGTCTGCCC TATCAACTTT-(TAMRA)-3′. The method has been described elsewhere.[17]

The primers used for reverse transcription (RT)–PCR were as follows: human 2′,5′-oligoadenylate synthetase (2′,5′-OAS): forward primer, 5′-CAATCAGCGAGGCC AGTAATC-3′ and reverse primer, 5′-TGGTGAGAAGTGC TGGGGTC-3′; human myxovirus resistance protein A (MxA): forward primer, 5′-GTCAGGAGT-TGCCCTT CCCA-3′ and reverse primer, 5′-GGCCCCTTCCTT ACCCTTA-3′; and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH): forward primer, 5′-GAAG GTGAAGGTCGGAGTC-3′ and reverse primer, 5′-CTT TAGGGTAGTGGTAGAAG-3′, respectively. Each reaction mixture contained cDNA (3 μL), 1.5 mM MgCl$_2$, 200 μM dNTP, 1 μM each primer, and 1.25 U AmpliTaq Gold (Applied Biosystems, USA) with 1× supplied reaction buffer. After activation of AmpliTaq Gold activity at 95°C for 10 min, the temperature cycling conditions for MxA were 29 cycles consisting of denaturation at 95°C for 30 s, annealing at 56°C for 1 min, and extension at 72°C for 1 min. For 2′,5′-OAS, the conditions were 32 cycles consisting of denaturation at 95°C for 30 s, annealing at 53°C for 1 min, and extension at 72°C for 1 min. For GAPDH, the conditions were 30 cycles consisting of denaturation at 95°C for 30 s, annealing at 53°C for 1 min, and extension at 72°C for 1 min. PCR products were subjected to electrophoresis in a 3% agarose gel.

Western blotting

Preparation of cell lysates, sodium dodecyl sulfate–polyacrylamide gel electrophoresis, and immunoblotting were performed as described previously.[18] The antibodies used in this study were the anti-NS3 antibody (Santa Cruz Biotechnology, USA) anti-NS5A antibody (Virogen, Watertown, MA, USA) and anti-β-actin antibody (Cell Signaling, Danvers, MA, USA). Alkaline phosphatase-conjugated secondary antibodies and CDP-Star chemiluminescent substrate (New England Biolabs, Beverly, MA, USA) were used for detection.

Cell cycle analysis

Harvested cells were washed once with phosphate-buffered saline (PBS) and fixed with 70% ethanol at 4°C for 1 h. After an additional wash, the cells were treated with 250 μg/mL RNase A at 37°C for 1 h and subsequently stained with 50 μg/mL propidium iodide at 4°C for 1 h. The DNA content was then analyzed by FACS-Calibur (BD Biosciences, Franklin Lakes, NJ, USA) with ModFit LT software (Verity Software House, Topsham, ME, USA).

Analyses of drug synergy

The effects of the treatment of Huh7/Rep-Feo cells with griseofulvin and IFNα, alone and in combination, were analyzed with CalcuSyn, a computer program based on the method of Chou and Talalay.[19] After converting the dose-effect curves for each drug or drug combination to median-effect plots, the program calculated a combination index (CI). The CI of <1, 1, and >1 indicate synergy, an additive effect, and antagonism, respectively.

Plasmids and stable transfection

The plasmid pEF-Fluc-IN was constructed as follows. The fragment carrying the firefly luciferase was amplified from the pGL3 control vector (Promega, USA) by PCR using a pair of primers (5′-GAATTCATGGAAGAC GCCAAAAACATAAA-3′ [EcoRI site] and 5′-GCGGC CGCTTACACGGCGATCTTTCCGCCC-3′ [NotI site]). The PCR product was cloned into the pGEM-T Easy vector (Promega, USA). The EMCV IRES Neo fragment was excised from the pMXs-IN vector by NotI and SalI digestion.[20] The EcoRI–SalI fragment of the pCHO vector was excised from the pGag-pol-IRES-bs′ vector by EcoRI and SalI digestion.[21] To construct pEF-Fluc-IB, the EcoRI–NotI fragment of firefly luciferase, and the NotI–SalI fragment of the EMCV IRES Neo were inserted into the EcoRI and the SalI site of pCHO by triple ligation.

The plasmid pEF Rluc-HCV IRES Feo was constructed as follows. The fragment carrying the Renilla luciferase was amplified from the phRL-TK vector (Promega, USA) by PCR using a pair of primers (5′-GAATTCATGGCT TCCAAGGTGTACGACCC-3′ [EcoRI site] and 5′-GGAT CCTTACTGCTCGTTCTTCAGCACGC-3′ [BamHI site]). The fragment carrying the HCV IRES Feo was amplified from the pRep-Feo vector[7] by PCR using a pair of primers (5′-GGATCCGCCAGCCCCCGATTGGGGGCG AC-3′ [BamHI site] and 5′-GTCGACTCAGAAGAAC TCGTCAAGAAGGC-3′ [SalI site]). Each PCR product was cloned into the pGEM-T Easy vector. To construct pEF Rluc-HCV IRES Feo, the EcoRI–BamHI fragment of Renilla luciferase, and the BamHI–SalI fragment of HCV IRES Feo were inserted into the EcoRI and SalI site of pCHO by triple ligation.

The pEF-Fluc-IB and pEF Rluc-HCV IRES Feo was transfected into Huh7 cells using Effectene transfection reagent (QIAGEN, Hilden, Germany), according to the manufacturer's recommendation. Two days after trans-

© 2008 The Japan Society of Hepatology

fection, the Huh7 cells were selected in a medium containing 250 μg/mL G418.

Immunofluorescent staining

After treatment with griseofulvin for 72 h, HCV JFH-1-infected cells were fixed with cold methanol and blocked using Blocking One (Nacalai Tesque, Kyoto, Japan). For the detection of the NS3 protein, the cells were incubated with the anti-NS3 antibody (Virogen, USA) for 1 h at room temperature. After washing with PBS, the cells were incubated with an Alexa Fluor 488 goat antimouse immunoglobulin G antibody (Molecular Probes, Eugene, OR, USA) for 1 h at room temperature. After washing with PBS, the cells were stained with 7-aminoactinomycin D for nuclear counterstaining, and analyzed using fluorescence microscopy.

RESULTS

Replication of a subgenomic HCV-1b replicon is suppressed by griseofulvin

WE INVESTIGATED THE anti-HCV effect and cell toxicity of griseofulvin in the HCV subgenomic replicon cells, Huh7/Rep-Feo. The luciferase activities of the Huh7/Rep-Feo cells showed that replication of the HCV replicon was suppressed by griseofulvin in a dose-dependent manner (Fig. 1a). Next, we performed a time-course experiment in which the luciferase activities of Huh7/Rep-Feo cells were measured at various time points after treatment with griseofulvin. As shown in Figure 1b, griseofulvin induced a decrease in the luciferase activities of Huh7/Rep-Feo cells over time. The treatment with griseofulvin had little effect on cellular viability at this range of concentration, as revealed by the MTS assay (Fig. 1c). The 50% effective concentration (EC_{50}) of griseofulvin was 6.13 ± 0.17 μM. The 50% cytotoxic concentration of this compound (CC_{50}) was 217.93 ± 3.49 μM. Thus the selectivity index (ratio of CC_{50} to EC_{50}) was 35.5 (Table 1). Furthermore, we examined the effect of other antifungal agents, fluconazole and itraconazole, on HCV-RNA replication. In contrast, fluconazole and itraconazole had little effect on HCV-RNA replication (Table 1).

We analyzed HCV-RNA levels in Huh7/Rep-Feo cells treated or not treated with griseofulvin using real-time RT–PCR. As shown in Figure 2a, treatment with griseofulvin decreased the replicon RNA titer in a dose-dependent manner. Similar results were seen at the protein level by monitoring the HCV non-structural proteins NS3 and NS5A. The Western blot analysis demon-

Figure 1 Inhibition of hepatitis C virus replication in Huh7/Rep-Feo cells by griseofulvin. (a) Huh7/Rep-Feo cells were cultured with various concentrations of griseofulvin in the medium and luciferase assays were performed after 72 h of culture. Luciferase assays were performed in triplicate. Error bars indicate mean ± standard deviation. (b) Huh7/Rep-Feo cells were treated with various concentrations of griseofulvin (2.5–40.0 μM). Luciferase activity was measured at the time points indicated after exposure to griseofulvin. (C) 5-(3-Carboxymethoxyphenyl)-2-(4,5-dimethylthiazoly)-3-(4-sulfophenyl) tetrazolium inner salt of Huh7/Rep-Feo cells cultured with the concentration of griseofulvin indicated.

Table 1 Antihepatitis C virus activities of oral antifungal agents in Huh7/Rep-Feo cells†

	EC$_{50}$ (μM)	CC$_{50}$ (μM)	SI
Griseofulvin	6.13 ± 0.17	217.93 ± 3.49	35.5
Fluconazole	135.6 ± 1.25	159.06 ± 1.07	1.2
Itraconazole	1.24 ± 0.21	3.35 ± 0.17	2.7

†All data represent means ± standard deviation for three separate experiments. CC$_{50}$, 50% cytotoxicity concentration based on the reduction of cell viability; EC$_{50}$, 50% effective concentration based on the inhibition of HCV replication; SI, selectivity index (CC$_{50}$/EC$_{50}$).

strated that griseofulvin treatment results in reduced levels of these viral proteins (Fig. 2b).

However, it remains to be clarified whether the griseofulvin inhibits firefly luciferase directly. To investigate this possibility, we examined the effect of griseofulvin on firefly luciferase activity using Huh7 cells expressing firefly luciferase constitutively. The treatment of these cells with griseofulvin resulted in no significant change in the firefly luciferase activity (Fig. 3). This result excludes the possibility that griseofulvin inhibits firefly luciferase activity directly.

Anti-HCV activity of griseofulvin is not mediated by the IFN signaling pathway

It has been reported that the HCV replicon is highly sensitive to IFN.[22,23] To determine whether the action of griseofulvin on the HCV subgenomic replicon involves the activation of IFN-stimulated gene responses, we analyzed the expression of IFN inducible genes in HCV replicon cells. The RT–PCR analysis showed that the messenger RNA for MxA and 2',5'-OAS, which are both IFN inducible genes, were induced by IFNα-2b, but not by griseofulvin (Fig. 4). These results suggest that the action of griseofulvin on the intracellular replication of HCV replicon is independent of the IFN signaling pathway.

Synergistic inhibitory effect of griseofulvin and IFNα on HCV replicon

Whether a combination of griseofulvin and IFNα exhibits a synergistic, additive, or antagonistic effect was assessed using an isobologram method.[19] An isobologram analysis is an approach used in preclinical studies to quantify the extent of synergistic, additive, or antagonistic effects between drugs used in combination. For instance, a representation of an isobologram to evaluate a drug–drug interaction is shown in Figure 5a. It is

understood that synergy, additivity, and antagonism are represented by concave, liner, and convex isoeffective curves (isoboles), respectively. The combined anti-HCV effects of griseofulvin and IFNα were evaluated. Prior to the combination experiments, the optimal concentration ratio of two compounds (combination ratio) had to be determined. After preliminary experiments, three different rations were chosen for each combination

Figure 2 Suppressive effect of griseofulvin for hepatitis C virus (HCV) replicon was confirmed by real-time reverse transcription–polymerase chain reaction (RT–PCR) and Western blot analysis. (a) Incubation of Huh7/Rep-Feo cells with griseofulvin for 72 h resulted in dose-dependent antiviral effects. Real-time RT–PCR was performed on the extracted RNA. HCV-RNA levels are shown as relative percentages of untreated control. Error bars indicate mean ± SD. (b) Western blot analyses of NS3 and NS5A protein expressions were performed on protein extracts from cells that were treated for 72 h with varying dose of griseofulvin. β-Actin was used as a loading control.

© 2008 The Japan Society of Hepatology